The U.S. Food and Drug Administration has approved Lifyorli (relacorilant) in combination with nab-paclitaxel for treating adults with platinum-resistant epithelial ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE